Citations

Clear

499 citation(s) found for "Tracy, PB".

Correlates of Fluctuations in Moderate-Advanced Dementia with Lewy Bodies (P13-6.007)
Tholanikunnel, Tracy , LaBarre, Brian , Sovich, Kaitlin , Paulson, Henry L. , Maixner, Susan M. , Manning, Carol A. , Fields, Julie A. , Lunde, Angela , Boeve, Bradley, Forsberg, Leah K. , Armstrong, Melissa J. , Paulson, Henry L , LaBarre, Brian , Armstrong, Melissa J , Li, Zhigang , Galvin, James E. , Taylor, Angela E.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202132 Get It

CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization
Luebker, Sarah, Frech, Tracy , Skaug, Brian , Gordon, Jessica , Lakin, Kimberly S. , Bernstein, Elana J. , Luo, Yiming , Steen, Virginia , Moore, Duncan F. , Khanna, Dinesh , Castelino, Flavia V. , Chung, Lorinda, Kapoor, Puneet, Hant, Faye N. , Shanmugam, Victoria K. , VanBuren, John M. , Alvey, Jessica S. , Harding, Monica, Shah, Ankoor R. , Lebiedz‐Odrobina, Dorota, Thomas, Julie K. , Volkmann, Elizabeth R. , Molitor, Jerry A., Sandorfi, Nora , Chung, Leland W.K. , Luo, Yiming , Frech, Tracy M , Skaug, Brian , Bernstein, Elana J , Richardson, Carrie , Khanna, Dinesh , Volkmann, Elizabeth R , Chung, Lorinda , Luo, Yiming , Assassi, Shervin , Luo, Yiming, Shah, Ami A. , Hummers, Laura K , Chung, Lorinda, Shah, Ankoor, Makol, Ashima , Thomas, Julie K

Mayo Clinic

Rheumatology | April 20, 2023 | Volume: 62 | Issue: 10 | Pages: 3433-3438

10.1093/rheumatology/kead176 | PMID 37079727 Get It

Abstract Objectives SSc is associated with increased health-care resource utilization and economic burden. The Collaborative National Quality and Efficacy Registry (CONQUER) is a US-based collaborative that collects longitudinal follow-up data on SSc patients with <5 years of disease duration enrolled at scleroderma centres in the USA. The objective of this study was to investigate the relationship between gastrointestinal tract symptoms and self-reported resource utilization in CONQUER participants. Methods CONQUER participants who had completed a baseline and 12-month Gastrointestinal Tract Questionnaire (GIT 2.0) and a Resource Utilization Questionnaire (RUQ) were included in this analysis. Patients were categorized by total GIT 2.0 severity: none-to-mild (0–0.49); moderate (0.50–1.00), and severe-to-very severe (1.01–3.00). Clinical features and medication exposures were examined in each of these categories. The 12-month RUQ responses were summarized by GIT 2.0 score categories at 12 months. Results Among the 211 CONQUER participants who met the inclusion criteria, most (64%) had mild GIT symptoms, 26% had moderate symptoms, and 10% severe GIT symptoms at 12 months. The categorization of GIT total severity score by RUQ showed that more upper endoscopy procedures and inpatient hospitalization occurred in the CONQUER participants with severe GIT symptoms. These patients with severe GIT symptoms also reported the use of more adaptive equipment. Conclusion This report from the CONQUER cohort suggests that severe GIT symptoms result in more resource utilization. It is especially important to understand resource utilization in early disease cohorts when disease activity, rather than damage, primarily contributes to health-related costs of SSc.
Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions
Lindström, Sara , Wang, Lu , Feng, Helian , Huo, Sijia , Harrison, Tabitha A. , Turman, Constance , Chen, Hongjie , Bammler, Theo K. , Gallinger, Steve, Gruber, Stephen B. , Moreno, Vı́ctor , Offit, Kenneth , O’Mara, Tracy A. , Tomlinson, Ian, Gharahkhani, Puya , MacGregor, Stuart , Schumacher, Johannes , Bondy, Melissa L. , Houlston, Richard S. , Jenkins, Robert B. , Melin, Beatrice , Wrensch, Margaret , Brennan, Paul , Johansson, Mattias , McKay, James , Aldrich, Melinda C. , Landi, Maria Teresa , Bishop, D. Timothy , Iles, Mark M. , Law, Matthew H. , Wolpin, Brian M. , Petersen, Gloria M. , Purdue, Mark P. , Scélo, Ghislaine , Kar, Siddhartha , Hung, Rayjean J, Kraft, Peter , Lissowska, Jolanta , Simard, Jacques , Dörk, Thilo , John, Esther M. , Carracedo, Ángel , Huang, Wen‐Yi , Vodička, Pavel , Taylor, Jack A. , Lessel, Davor , Kurian, Allison W. , Hung, Rayjean J. , Kundaje, Anshul , Zhong, Jun , Turman, Constance , Chen, Hongjie , Gruber, Stephen B , Marchand, Loïc Le , Moreno, Victor , Offit, Kenneth , Gharahkhani, Puya , MacGregor, Stuart , Schumacher, Johannes , Houlston, Richard S , Brennan, Paul , Johansson, Mattias , Iles, Mark M , Law, Matthew H , Amundadottir, Laufey , Klein, Alison P , Petersen, Gloria, Chanock, Stephen Jacob , Kar, Siddhartha , Kraft, Peter , Dörk, Thilo , Lissowska, Jolanta , John, Esther M , Hung, Rayjean J , Harrison, Tabitha A , O'Mara, Tracy A , Lessel, Davor , Bishop, D Timothy , Huang, Wen-Yi , Taylor, Jack A , Simard, Jacques , Kurian, Allison W , Kundaje, Anshul , Vodicka, Pavel , Zhong, Jun , Majumdar, Arunabha , MacDonald, James W. , Mancuso, Nicholas , Gunter, Marc J. , Marchand, Loı̈c Le , Vivo, Immaculata De , Spurdle, Amanda B. , Fitzgerald, Rebecca C. , Gockel, Ines , Jankowski, Janusz , Barnholtz‐Sloan, Jill S. , Christiani, David C. , Amos, Christopher I. , Tardón, Adonina , Démenais, Florence , Goldstein, Alisa M. , Kanetsky, Peter A. , Ámundadóttir, Laufey T. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Risch, Harvey A. , Pharoah, Paul D.P. , Paşaniuc, Bogdan

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 17, 2023 | Volume: 115 | Issue: 6 | Pages: 712-732

10.1093/jnci/djad043 | PMID 36929942 Get It

Abstract Background The shared inherited genetic contribution to risk of different cancers is not fully known. In this study, we leverage results from 12 cancer genome-wide association studies (GWAS) to quantify pairwise genome-wide genetic correlations across cancers and identify novel cancer susceptibility loci. Methods We collected GWAS summary statistics for 12 solid cancers based on 376 759 participants with cancer and 532 864 participants without cancer of European ancestry. The included cancer types were breast, colorectal, endometrial, esophageal, glioma, head and neck, lung, melanoma, ovarian, pancreatic, prostate, and renal cancers. We conducted cross-cancer GWAS and transcriptome-wide association studies to discover novel cancer susceptibility loci. Finally, we assessed the extent of variant-specific pleiotropy among cancers at known and newly identified cancer susceptibility loci. Results We observed widespread but modest genome-wide genetic correlations across cancers. In cross-cancer GWAS and transcriptome-wide association studies, we identified 15 novel cancer susceptibility loci. Additionally, we identified multiple variants at 77 distinct loci with strong evidence of being associated with at least 2 cancer types by testing for pleiotropy at known cancer susceptibility loci. Conclusions Overall, these results suggest that some genetic risk variants are shared among cancers, though much of cancer heritability is cancer-specific and thus tissue-specific. The increase in statistical power associated with larger sample sizes in cross-disease analysis allows for the identification of novel susceptibility regions. Future studies incorporating data on multiple cancer types are likely to identify additional regions associated with the risk of multiple cancer types.
Abstract P540: Cardiovascular Disease Risk Factors and Antibody Response to COVID-19 Vaccination: The C4R Study
Sun, Yifei , Cushman, Mary , Styer, Linda M. , Anderson, Michaela R. , Elkind, Mitchell S, Ortega, Victor E. , Woodruff, Prescott G. , Cole, Shelley, Parker, Monica M. , Kim, John S. , Balte, Pallavi , Tracy, Russell P. , Allen, Norrina B. , Schreiner, Pamela J. , Bowler, Russell P. , Schwartz, David A. , Lee, Joyce , Xanthakis, Vanessa , Doyle, Margaret F. , Kanaya, Alka M , Howard, Virginia J. , Mantis, Nicholas J , Barr, R. Graham , Oelsner, Elizabeth C. , Demmer, Ryan T.

Mayo Clinic

Circulation | March 14, 2023 | Volume: 147 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.147.suppl_1.p540 Get It

Background: Adults with cardiovascular co-morbidities and risk factors are at greater risk of severe COVID-19. These same risk factors may also be associated with an attenuated antibody response to COVID-19 vaccines, although studies in diverse, U.S. population-based cohorts have been limited. Methods: The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) conducted a serosurvey for SARS-CoV-2 antibodies via dried blood spot (DBS) in 14 U.S. cohorts. IgG antibodies to SARS-CoV-2 spike subunit 1 (S1) and nucleocapsid (N) were measured from DBS using a semi-quantitative microsphere immunoassay and reported as median fluorescence intensity (MFI). Multivariable adjusted linear models regressed log-transformed anti-S1 MFI on age, sex, race/ethnicity, education attainment, self-reported diabetes, hypertension, cardiovascular disease (CVD), chronic kidney disease, smoking history, body mass index (BMI), asthma, obstructive lung diseases, DBS batch, anti-N MFI, vaccine type, time between vaccine and DBS, and vaccine dose at time of DBS collection. Results are presented as the percent difference in anti-S1 MFI compared with a reference group. Results: There were 6614 vaccinated participants prior to booster regimens and DBS collection (April 2021-July 2022) with 50%, 48%, and 2% of the cohort who received BNT162b2, mRNA-1273, or other vaccines, respectively. The mean (SD) time between vaccination and DBS was 3.8 (1.8) months. Over 10% of the cohort had self-reported a history of diabetes, 55% had hypertension, and 74% had a BMI>25 kg/m 2 . Anti-S1 MFI decreased as the time between vaccine dose and DBS collection increased. Diabetes was associated with a 16.1% lower anti-S1 MFI (95%CI:-22.4,-9.5) whereas neither hypertension (-3.8%;95%CI:-9.3,2.1), nor cardiovascular disease history (-5.3%;95%CI:-16.3,7.4) were associated with anti-S1 MFI. Former and current smoking history were each associated with a lower anti-S1 MFI: (-6.6%;95%CI:-12.1,-0.8) and (-16.1%;95%CI:-24.7,-6.6), respectively. Participants with a BMI 25-29.9 kg/m 2 had a 7.6% higher anti-S1 MFI (95%CI:0.3,15.4) whereas those with a BMI of 30-35 kg/m 2 and >35 kg/m 2 had 6.2% (95%CI:-2.4,15.5) higher and 8.9% lower (95%CI:-17.6,0.7) MFI levels, respectively. Older age and male sex were each associated with a lower anti-S1 MFI and mRNA-1273 vaccine, Asian subgroup, higher anti-N titer, and prior COVID-19 infection were each associated with higher anti-S1 MFI. Chronic kidney disease, education attainment, and lung disease were not associated with anti-S1 MFI. Conclusions: Several traditional cardiovascular disease risk factors were associated with diminished humoral responses to the initial COVID-19 vaccine regimens in a diverse U.S. population-based cohort and may have implications on strategies to improve vaccine responses.
Patient‐reported experiences with migraine‐related cognitive symptoms: Results of the MiCOAS qualitative study
Gerstein, Maya T. , Uzumcu, Alyssa, McGinley, James S., Buse, Dawn C. , Cooke, Alexis , Touba, Nancy M., Nishida, Tracy K., Dodick, David W , Lipton, R.B. , Wirth, Robert J. , Houts, Carrie R. , McCarrier, Kelly P. , Goadsby, Peter J. , Dodick, David W. , Lipton, Richard B.

Mayo Clinic

Headache: The Journal of Head and Face Pain | March 11, 2023 | Volume: 63 | Issue: 3 | Pages: 441-454

10.1111/head.14484 | PMID 36905166 Get It

Abstract Objectives To capture patients' perspectives on migraine‐related cognitive symptoms during pre‐headache, headache, post‐headache, and interictal periods. Background Migraine‐related cognitive symptoms are reported by people with migraine both during and between attacks. Associated with disability, they are increasingly viewed as a priority target for treatment. The Migraine Clinical Outcome Assessment System (MiCOAS) project is focused on developing a patient‐centered core set of outcome measures for the evaluation of migraine treatments. The project focuses on incorporating the experience of people living with migraine and the outcomes most meaningful to them. This includes an examination of the presence and functional impact of migraine‐related cognitive symptoms and their perceived impact on quality of life and disability. Methods Forty individuals with self‐reported medically diagnosed migraine were recruited via iterative purposeful sampling for semi‐structured qualitative interviews conducted using audio‐only web conferencing. Thematic content analysis was performed to identify key concepts around migraine‐related cognitive symptoms. Recruitment continued until concept saturation was achieved. Results Participants described symptoms consistent with migraine‐related deficits in language/speech, sustained attention, executive function, and memory that manifest during pre‐headache (36/40 [90%] reported ≥1 cognitive feature), headache (35/40 [88%] reported ≥1 cognitive feature), post‐headache (27/40 [68%] reported ≥1 cognitive feature), and interictal periods (13/40 [33%] reported ≥1 cognitive feature). Among participants reporting cognitive symptoms during pre‐headache, 32/40 (81%) endorsed 2–5 cognitive symptoms. Findings were similar during the headache phase. Participants reported language/speech problems consistent with, for example, impairments in receptive language, expressive language, and articulation. Issues with sustained attention included fogginess, confusion/disorientation, and trouble with concentration/focus. Deficits in executive function included difficulty processing information and reduced capacity for planning and decision‐making. Memory issues were reported across all phases of the migraine attack. Conclusions This patient‐level qualitative study suggests that cognitive symptoms are common for persons with migraine, particularly in the pre‐headache and headache phases. These findings highlight the importance of assessing and ameliorating these cognitive problems.
International Consensus Statement on the Radiological Screening of Contact Children in the Context of Suspected Child Physical Abuse
Mankad, Kshitij , Sidpra, Jai , Oates, Adam , Kan, Elaine , Agrawal, Nina, Kelly, Patrick J. , Zeitlin, Deborah, Carter, Jamieson, Debelle, Geoff , Berger, Rachel P. , Christian, Cindy W. , Lindberg, Daniel M. , Raissaki, Maria , Argyropoulou, Maria I. , Adamsbaum, C. , Cain, Timothy , Silvera, V. Michelle , Kemp, Alison , Choudhary, Arabinda K. , Offiah, Amaka C , Mirsky, David M. , Colleran, Gabrielle , Lucato, Leandro Tavares , Kilborn, Tracy , Teeuw, Arianne Hélène , Zeitlin, Deborah, Carter, Jamieson, Rijn, Rick Robert van , Rossi, Andrea

Mayo Clinic

JAMA Pediatrics | March 6, 2023 | Volume: 177 | Issue: 5 | Pages: 526

10.1001/jamapediatrics.2022.6184 | PMID 36877504 Get It

Importance Physical abuse is a common but preventable cause of long-term childhood morbidity and mortality. Despite the strong association between abuse in an index child and abuse in contact children, there is no guidance outlining how to screen the latter, significantly more vulnerable group, for abusive injuries. Consequently, the radiological assessment of contact children is often omitted, or variably performed, allowing occult injuries to go undetected and increasing the risk of further abuse. Objective To report an evidence-based and consensus-derived set of best practices for the radiological screening of contact children in the context of suspected child physical abuse. Evidence Review This consensus statement is supported by a systematic review of the literature and the clinical opinion of an internationally recognized group of 26 experts. The modified Delphi consensus process comprised 3 meetings of the International Consensus Group on Contact Screening in Suspected Child Physical Abuse held between February and June 2021. Findings Contacts are defined as the asymptomatic siblings, cohabiting children, or children under the same care as an index child with suspected child physical abuse. All contact children should undergo a thorough physical examination and a history elicited prior to imaging. Contact children younger than 12 months should have neuroimaging, the preferred modality for which is magnetic resonance imaging, and skeletal survey. Contact children aged 12 to 24 months should undergo skeletal survey. No routine imaging is indicated in asymptomatic children older than 24 months. Follow-up skeletal survey with limited views should be performed if abnormal or equivocal at presentation. Contacts with positive findings should be investigated as an index child. Conclusions and Relevance This Special Communication reports consensus recommendations for the radiological screening of contact children in the context of suspected child physical abuse, establishing a recognized baseline for the stringent evaluation of these at-risk children and providing clinicians with a more resilient platform from which to advocate for them.
Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates
Makower, Della , Albain, Kathy S. , Hayes, Daniel F. , Dees, Elizabeth Claire , Lively, Tracy , Saphner, Thomas J. , Whelan, Timothy J. , Kaklamani, Virginia , Sparano, Joseph A. , Gray, Robert J. , Geyer, Charles E. , Goetz, Matthew P. , Olson, John A. , Badve, Sunil , Wagner, Lynne I. , Sledge, George W. , Whelan, Timothy J

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: GS1-05-GS1-05

10.1158/1538-7445.sabcs22-gs1-05 Get It

Abstract Background: Late recurrence of breast cancer after 5 years accounts for about 50% of recurrences in hormone receptor (HR)-positive early breast cancer (EBC). TAILORx established non-inferiority of adjuvant endocrine therapy (ET) given for at least 5 years to chemotherapy plus ET (CET) in EBC and a 21-gene recurrence score (RS) of 11-25, although there was some chemotherapy benefit in women Methods: Eligibility criteria included women 18-75 years with HR-positive, HER2-negative, T1b-T2N0 EBC who agreed to have CT assigned or randomized based on the RS assay. The primary endpoint was invasive disease-free survival (iDFS) in the RS 11-25 group. The “primary analysis” refers to the original prespecified analysis for the primary IDFS endpoint (836 IDFS events at full information in the RS 11-25 group) after a median of 7.5 years. The “updated analysis” was performed after a median followup of 11.0 and 10.4 years in the randomized and overall populations, respectively. Results:10,253 eligible women enrolled between 4/7/06-10/6/10.The updated analysis includes substantially more events that the primary analysis, including IDFS events (1819 vs. 1210), distant recurrences (561 vs. 384), locoregional +/- distant recurrences (764 vs. 543), and deaths (910 vs. 499). The table provides 5 and 12-year event rates (and standard errors) for all arms, and comparisons of the randomized arms. The primary trial conclusions remain unchanged: ET was non-inferior to CET in the randomized group with a RS 11-25. Although recurrence occurred in < 10% by 12 years for a RS 0-25, late recurrence events beyond 5 years exceeded earlier recurrence. Non-recurrence events occurred in about 13% at 12 years (~1%/year), contributing substantially to the IDFS rates. For women Conclusions: The current updated analysis confirms findings from the original primary analysis that ET is non-inferior to CET in HR-positive, HER2-negative, node-negative EBC and a RS 11-25. As in the original primary analysis, the subgroup of women Citation Format: Joseph Sparano, Robert J. Gray, Della Makower, Kathy S. Albain, Daniel F. Hayes, Charles Geyer, Elizabeth Dees, Matthew P. Goetz, John A. Olson Jr, Tracy G. Lively, Sunil Badve, Thomas Saphner, Lynne I. Wagner, Timothy Whelan, Virginia Kaklamani, George Sledge. Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr GS1-05.
Pediatric Chemotherapy Infusions in Outpatient Examination Rooms: A Novel Patient Care Approach
Omdahl, Tami K., Stenzel, Janelle L., Pike, Marsha L., Conlon, Patricia M. , Barry, Tracy A., Brown, Tanya M. , Cambern, Kari L., Davis, Kadi M., Fjerstad, Kelly A., Graner, Kevin, Larson, Alison P., Soefje, Scott A. , Janssen, Alan M., Graner, Kevin K, Kuhn, Alexis K , Orandi, Amir B , Smith, Emily L., Soefje, Scott A , Omdahl, Tami K, Kuhn, Alexis , Orandi, Amir B. , Smith, Emily L.

Mayo Clinic

Journal of Pediatric Hematology/Oncology Nursing | February 13, 2023 | Volume: 40 | Issue: 3 | Pages: 195-202

10.1177/27527530221140067 | PMID 36775936 Get It

Background: Many health care organizations offer pediatric infusions in outpatient infusion centers or, as in our organization, in a hospital-based outpatient Pediatric Infusion Therapy Center (PITC). When restrictions related to the COVID-19 pandemic decreased our PITC appointment capacity by 40%, other patient and family satisfaction issues were exacerbated. We implemented a new approach to pediatric infusions with the aim of improving patient and family satisfaction and reducing the amount of time in an appointment itinerary without negatively affecting patient safety. Methods: Our team used a phased approach to pilot the administration of short chemotherapy infusions in the same outpatient clinic examination rooms where consultation and routine office visits were conducted. Patients saw their specialist for an examination and, if clinically indicated, their infusion was administered in the same room. Appointment itineraries were then completed. The team tracked efficiency, satisfaction, and safety metrics related to the new process. Results: All efficiency metrics improved. No harm came to the 49 unique patients who received a total of 184 infusions. Patient appointment itineraries were shortened by an average of 1.03 hr. Satisfaction survey responses indicated a clear preference (93%) for the new process. Discussion: The novel approach of offering short infusions in outpatient clinic examination rooms provides an opportunity to ease capacity constraints and further increase patient and family satisfaction. This method may be especially helpful for health care organizations when external influences (e.g., lack of physical space, challenging patient volumes, and pandemics) necessitate a change.
Design and quality control of large-scale two-sample Mendelian randomization studies
Haycock, Philip , Borges, Maria Carolina , Burrows, Kimberley , Harrison, Sean , Burgess, Stephen , Chang, Xuling , Khankari, Nikhil K. , Tsilidis, Kostas K, Gaunt, Tom R. , Hemani, Gibran , Zheng, Jie , Truong, Thérèse , Law, Matthew H. , Mariosa, Daniela , Hung, Rayjean J, Smith, George Davey , Relton, Caroline L. , Martin, Richard M. , Peters, Ulrike , Rice, Terri, Gallinger, Steve, Cornish, Alex J. , Vijayakrishnan, Jayaram , Wrensch, Margaret , Korat, Andres V Ardisson , Wheeler, Bill, Nilsson, Björn , Smith, Caren E. , Riadi, David, Claus, Elizabeth B. , Hosnijeh, Ng, Irene Oi‐Lin , Passow, Jeanette E, Han, Jiali , Schildkraut, Joellen M. , Wiemels, Joseph L. , Yang, Keming , Wu, Lang , Boutron, Marie-Christine, Iles, Mark M. , Stanulla, Martin , Gaudet, Mia M., Lenha, Mobuchon, Camp, Nicki J, Sham, Pak C. , Brennan, Paul , Jenkins, Robert B. , Diskin, Sharon J. , Berndt, Sonja I. , Tsavachidis, Spiridon, Channock, Stephen J., Galesloot, Tessel E. , Haycock, Philip , Harrison, Sean , Chang, Xuling , Zheng, Jie , Law, Matthew H , Birmann, Brenda M , Mariosa, Daniela , Zheng, Wei , Davey Smith, George , Borges, Maria C , Martin, Richard M , Iles, Mark M , Truong, Therese , Lemaître, Rozenn N. , Westra, Jason , Tsilidis, Kostas K, O’Mara, Tracy A. , Spurdle, Amanda B. , Slager, Susan L. , Birmann, Brenda M. , Hosnijeh, Fatemeh Saberi , Amos, Christopher I. , Hung, Rayjean J, Zheng, Wei , Gunter, Marc J. , Tintle, Nathan , Cheng, Iona C. , Jenkins, Mark A. , Sud, Amit , Johansson, Mattias , Norman, Aaron D. , Klein, Alison P. , Clay‐Gilmour, Alyssa , Franke, André , Heng, Chew‐Kiat , Song, Ci , Ellinghaus, Eva , Ostroumova, Evgenia , Vathaire, Florent de , Cugliari, Giovanni , Matullo, Giuseppe , Cerhan, James R. , Passow, Jeanette E. Eckel, Foo, Jia Nee , Liu, Jianjun , Barnholtz‐Sloan, Jill S. , Maris, John M. , Hemminki, Kari , Kiemeney, Lambertus A. , Ámundadóttir, Laufey T. , Stern, Marc‐Henri , Purdue, Mark P. , Bondy, Melissa L. , Guénel, Pascal , Taylor, Philip R. , Gharahkhani, Puya , Ostrom, Quinn T. , Stolzenberg‐Solomon, Rachael Z. , Dorajoo, Rajkumar , Houlston, Richard S. , Enroth, Stefan , Harrison, Tabitha A. , Gyllensten, Ulf B , Vijai, Joseph , Shi, Yufang , Yang, Wenjian , Lin, Yi , Van Den Eeden, Stephen K

Mayo Clinic

International Journal of Epidemiology | February 11, 2023 | Volume: 52 | Issue: 5 | Pages: 1498-1521

10.1093/ije/dyad018 | PMID 38587501 Get It

Abstract Background Mendelian randomization (MR) studies are susceptible to metadata errors (e.g. incorrect specification of the effect allele column) and other analytical issues that can introduce substantial bias into analyses. We developed a quality control (QC) pipeline for the Fatty Acids in Cancer Mendelian Randomization Collaboration (FAMRC) that can be used to identify and correct for such errors. Methods We collated summary association statistics from fatty acid and cancer genome-wide association studies (GWAS) and subjected the collated data to a comprehensive QC pipeline. We identified metadata errors through comparison of study-specific statistics to external reference data sets (the National Human Genome Research Institute-European Bioinformatics Institute GWAS catalogue and 1000 genome super populations) and other analytical issues through comparison of reported to expected genetic effect sizes. Comparisons were based on three sets of genetic variants: (i) GWAS hits for fatty acids, (ii) GWAS hits for cancer and (iii) a 1000 genomes reference set. Results We collated summary data from 6 fatty acid and 54 cancer GWAS. Metadata errors and analytical issues with the potential to introduce substantial bias were identified in seven studies (11.6%). After resolving metadata errors and analytical issues, we created a data set of 219 842 genetic associations with 90 cancer types, generated in analyses of 566 665 cancer cases and 1 622 374 controls. Conclusions In this large MR collaboration, 11.6% of included studies were affected by a substantial metadata error or analytical issue. By increasing the integrity of collated summary data prior to their analysis, our protocol can be used to increase the reliability of downstream MR analyses. Our pipeline is available to other researchers via the CheckSumStats package (https://github.com/MRCIEU/CheckSumStats).
Evaluation of Associations of Growth Differentiation Factor-11, Growth Differentiation Factor-8, and Their Binding Proteins, Follistatin and Follistatin-Like Protein-3, With Measures of Skeletal Muscle Mass, Muscle Strength, and Physical Function in Older
Cawthon, Peggy M. , Patel, Sheena, Bhasin, Shalender , Peng, Liming , Lee, Se‐Jin , Ferrucci, Luigi , Ganz, Peter , Cummings, Steven R. , Newman, Anne B. , Bhasin, Shalinder , Ferrucci, Luigi , Ganz, Peter , Cawthon, Peggy , Tracy, Russell P. , Kizer, Jorge R. , LeBrasseur, Nathan K.

Mayo Clinic

The Journals of Gerontology: Series A | February 8, 2023 | Volume: 78 | Issue: 11 | Pages: 2051-2059

10.1093/gerona/glad045 | PMID 36752218 Get It

Abstract Background Based on studies from animal models, growth differentiation factor-11 (GDF-11) may have rejuvenating effects in humans. GDF-11 has high sequence homology with GDF-8 (also known as myostatin); follistatin and follistatin-like protein-3 (FSTL-3) are inhibitory proteins of both GDF-8 and GDF-11. Methods Using highly specific liquid chromatography with tandem mass spectrometry assays for GDF-11 and GDF-8 and immunoassays for follistatin and FSTL-3, we quantified the association of these factors with muscle size, strength, and physical performance in 2 prospective cohort studies of community-dwelling older adults (Health, Aging, and Body Composition study [Health ABC] and Cardiovascular Health Study [CHS]). Results GDF-8 levels were positively associated with thigh muscle cross-sectional area and density in Health ABC (data not available in CHS). GDF-8 levels were positively associated with lean mass (a surrogate of muscle mass) in Health ABC but not CHS, and grip strength in CHS but not Health ABC. FSTL-3 (and perhaps follistatin) was negatively associated with lean mass and had variable associations with other variables. In contrast, GDF-11 was not significantly associated with strength or performance. Conclusions GDF-8 and its binding proteins, follistatin and FSTL-3, may constitute a counterregulatory system (chalones) to restrain age-related loss of muscle mass and strength.